Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study. Tests the hypothesis that solanezumab, administered as an intravenous infusion at a dose of 400 mg every 4 weeks for 3 years, will slow cognitive decline as compared with placebo in s ...

Designed as both a cross-sectional and longitudinal study to follow unarmed professional combatants participating in either boxing and mixed martial arts fighting, retired professional combatants and a matched control group that has not participated in co ...

Observational study (age 55-90)

(age 50-90)

(age 60-85)

(age 50-85)

Exercise Study (age 65-89)

Registry for APOE Genotype (age 55-75)

(age 60-75)

(age 65 and up) Imaging dementia for amyloid scanning

(age 50-85)

(age 50-90)

Participants are randomly assigned to one of two groups for either no physical therapy or physical therapy (comprehensive program that includes aerobic, strength, gait, and balance training plus patient education) intervention for a period of 6 weeks. Aft ...